Rheumatoid Arthritis Clinical Trials in Philadelphia

Showing 3281-3300 of 3,895 trials

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

NCT00326664

This phase I trial is studying the side effects and best dose of AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System Germ Cell TumorChildhood Cerebral Anaplastic Astrocytoma+18 more

National Cancer Institute (NCI)55 participantsStarted Mar 2006

San Francisco, California, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +8 more locations

COMPLETEDPhase 2< 1 mile

Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days

NCT01953679

To compare the pharmacodynamic effects of 2 continuous dose regimens of ulipristal acetate 5.0 and 10.0 mg-only oral contraception, versus a 24/4 day regimen of UPA 5.0 mg.

Focus: Estrogen-free Oral Contraception

Premier Research180 participantsStarted Mar 2014

Los Angeles, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +7 more locations

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days

Rheumatoid Arthritis Trials in Other Cities

Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

GORE Flow Reversal System and GORE Embolic Filter Extension Study

Blood and Marrow Transplant Clinical Research Network

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months

The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine

Impact of Feeding on Pro-Inflammatory Cytokine Response in Neonates Receiving a RBC Transfusion

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)

Retrospective Multicenter Study to Determine 4-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-05 Study

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel

A Multi-Site Clinical Evaluation of the ARIES Flu Assay in Symptomatic Patients

Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib

A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Intradiscal rhGDF-5 Phase I/II Clinical Trial

104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants

Other Conditions in Philadelphia